Rx Fraud Investigations Could Get Boost From Health Care Reform's Transparency Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
Former DoJ prosecutor Michael Loucks says there is pressure from Congress to exclude companies from government programs, particularly if they have prior settlements with the government.
You may also be interested in...
FDA's Executive Responsibility Policy Could Sweep In Board Members
Add board members to the list of company executives who could be personally affected by FDA's plans to focus on responsible individuals in the corporations it takes to task as part of its enforcement mission.
Reform's "Sunshine" Clause Prompts Firms To Review Disclosure Web Sites
Any drug, device or medical supply company that sells products to a government program and provides payments or items worth more than $10 to practicing physicians or teaching hospitals will be required to post those outlays in a publicly-available database starting in 2013
The Era Of Big Pharma Fraud Cases Is Ending, Former U.S. Attorney Loucks Says - But It May End With A Bang
The wave of massive health care fraud settlements involving biopharmaceutical companies appears to be drawing to a close - but pressure for more draconian penalties means it may end with a bang